Grants |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Government Assistance [Abstract] | |
| Grants | 11. Grants
The Company recorded grant revenue of $0 during the three months ended March 31, 2026, and $278,628 during the three months ended March 31, 2025 in connection with a $2,500,000 grant from the State of Tennessee (the “Tennessee Grant”). The Tennessee Grant was provided as reimbursement of research and development expenses related to the development of animal health drug products. All grant revenue related to the Tennessee Grant was recognized at June 30, 2025. No additional revenue will be recognized for expenses incurred in connection with the Tennessee Grant. As of March 31, 2026 and December 31, 2025, the Company did not have any unearned grant revenue liability on the accompanying condensed consolidated balance sheet.
|